Investors of Vistagen Therapeutics Urged to Act Before Securities Class Action Deadline

Urgent Action Required for Vistagen Therapeutics Investors

Faruqi & Faruqi, LLP, a prominent national firm in securities law, is actively investigating potential legal claims against Vistagen Therapeutics, Inc. (NASDAQ: VTGN). Investors who purchased shares of Vistagen between April 1, 2024, and December 16, 2025, are being urged to evaluate their options in light of a federal securities class action lawsuit that has been initiated against the company. The critical deadline for claiming the role of lead plaintiff in this litigation is March 16, 2026.

Context and Allegations

The lawsuit highlights allegations that Vistagen and its executives made misleading statements regarding the company's clinical trials, specifically related to its drug fasedienol. According to the complaint, the company claimed that its previous trials had demonstrated a strong likelihood of success for the PALISADE-3 clinical trial, which was aimed at treating social anxiety disorder (SAD). However, the results released on December 17, 2025, countered these claims, showing that the study failed to meet primary efficacy endpoints. The announcement of these disappointing results caused Vistagen's stock price to plummet by over 81%, resulting in severe financial losses for many investors.

What Investors Should Know

The law firm Faruqi & Faruqi points out that any investor identifying with the class may motion the court to serve as lead plaintiff through their chosen counsel. Alternatively, individuals who prefer to take a passive role can choose not to respond. It is important to note that the potential recovery in the class action remains unaffected regardless of whether one decides to pursue leadership in the case. The key point is to stay informed about the ongoing litigation process and to consider legal consultation if significant financial stakes are involved.

Importance of the Role of Lead Plaintiff

The role of lead plaintiff is crucial in class actions, as this individual will be responsible for directing the case and making decisions on behalf of all class members. The lead plaintiff must be someone who has the largest financial interest in the outcome of the litigation and can adequately represent the collective interests of the class. Thus, it is vital for affected investors to consider their legal rights and options earnestly during this critical period.

Encouragement for Potential Whistleblowers

Faruqi & Faruqi is also encouraging any person who has insider information regarding Vistagen's operations—be it former employees, shareholders, or whistleblowers—to reach out to the firm for consultation. This could aid not only in strengthening the case but also in ensuring that justice is served for the affected investors.

Conclusion and Next Steps

In conclusion, if you are an investor in Vistagen Therapeutics during the specified time frame, it is imperative to understand your rights in this ongoing legal situation. Contacting Faruqi & Faruqi directly through their provided channels could provide clarity on your potential involvement in the class action. Make sure to act before the March 16, 2026, deadline to safeguard your investments and seek proper legal redress.

For further details on the case and to follow updates, investors can visit Faruqi & Faruqi's website or reach out to partner Josh Wilson at the number provided in their latest release.